COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Coronavirus Guidance for NIH Applicants and Grantees:

Dr. Manzoor Zarger

Dr. Manzoor Zarger

Scientific Review Officer


Division of Basic and Integrative Biological Sciences DBIB
Oncology 1 Basic Translational OBT
Study Section:
Cancer Molecular Pathobiology CAMP

Dr. Manzoor A. Zarger received training through the CSR Review Internship Program and is now a Scientific Review Officer overseeing the Cancer Molecular Pathobiology study section in the Oncology 1-Basic Translational Integrated Review Group.

He has been the Scientific Review Officer for the Tumor Progression and Metastasis study section, the Drug Discovery and Molecular Pharmacology study section and the Oncology Fellowships study section. Before coming to CSR, he was a senior research scientist at the National Institute of Allergy and Infectious Disease, where he was involved in deciphering the critical role of caspase 8 in T cell activation rather than its well-characterized function in cell death. Prior to this position, he was director of the Molecular Oncology Laboratory at King Faisal Specialist Hospital and Research Center, where he directed research on the therapeutic potential of TRAIL in various cancers. After receiving a Ph.D. in biochemistry and molecular biology, Dr. Zarger conducted his postdoctoral studies at Thomas Jefferson University, where he was at the forefront of apoptosis research discovering various caspases, death receptors, and anti-apoptotic molecules, and their roles in various forms of cell death. He has published his research findings in prestigious journals like Cell, Nature, Molecular Cell, PNAS, JBC, and Cancer Research.